Details of the Drug

General Information of Drug (ID: DMJIH83)

Drug Name

XmAb20717

Synonyms

XmAb717

Indication

Disease Entry	ICD 11	Status	REF
Advanced malignancy	2A00-2F9Z	Phase 1	[1]
Breast cancer	2C60-2C65	Phase 1	[2]
Melanoma	2C30	Phase 1	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4)	TTI2S1D	CTLA4_HUMAN	Not Available	[3]
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Advanced malignancy

ICD Disease Classification

2A00-2F9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Cytotoxic T-lymphocyte protein 4 (CTLA-4)	DTT	CTLA4	4.05E-03	-0.21	-1.52

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
2	ClinicalTrials.gov (NCT03517488) A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2). U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of Xencor.